Stock Plans

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Note 12. Stock Plans

Under our Amended and Restated 2005 Performance Incentive Plan (the “Plan”), we are authorized through May 21, 2024 to issue a maximum of 243.7 million shares of our Common Stock to employees and non-employee directors. As of December 31, 2020, there were 53.2 million shares available to be granted under the Plan.

Stock Options:

Stock options (including stock appreciation rights) are granted at an exercise price equal to the market value of the underlying stock on the grant date, generally become exercisable in three annual installments beginning on the first anniversary of the grant date and have a maximum term of ten years.

We account for our employee stock options under the fair value method of accounting using a Black-Scholes methodology or a Lattice Model to measure stock option expense at the date of grant. The fair value of the stock options at the date of grant is amortized to expense over the vesting period. We recorded compensation expense related to stock options held by our employees of $28 million in 2020, $38 million in 2019 and $43 million in 2018 in our results from continuing operations. The deferred tax benefit recorded related to this compensation expense was $5 million in 2020, $8 million in 2019 and $7 million in 2018. The unamortized compensation expense related to our employee stock options was $23 million at December 31, 2020 and is expected to be recognized over a weighted-average period of 1.4 years.

Our weighted-average Black-Scholes and Lattice Model fair value assumptions were:


	Risk-Free Interest Rate		Expected Life	Expected Volatility		Expected Dividend Yield		Fair Value at Grant Date
2020	1.34	%	5 years	19.64	%	2.06	%	$	8.61
2019	2.46 %		5 years	19.96 %		2.37 %		$	7.83
2018	2.68 %		5 years	20.96 %		2.02 %		$	8.30

The risk-free interest rate represents the constant maturity U.S. government treasuries rate with a remaining term equal to the expected life of the options. The expected life is the period over which our employees are expected to hold their options. Volatility reflects historical movements in our stock price for a period commensurate with the expected life of the options. The dividend yield reflects the dividend yield in place at the time of the historical grants.

Stock option activity is reflected below:


	Shares Subject to Option	Weighted- Average Exercise or Grant Price Per Share		Average Remaining Contractual Term	Aggregate Intrinsic Value
Balance at January 1, 2018	48,434,655	$	29.92		$	626	million
Annual grant to eligible employees	5,666,530	43.51
Additional options issued	168,306	31.40
Total options granted	5,834,836	43.16
Options exercised (1)	(9,333,271)	25.16			$	170	million
Options cancelled	(1,117,390)	42.93
Balance at December 31, 2018	43,818,830	32.36			$	371	million
Annual grant to eligible employees	4,793,570	47.72
Additional options issued	68,420	50.82
Total options granted	4,861,990	47.76
Options exercised (1)	(13,668,354)	27.53			$	306	million
Options cancelled	(1,156,518)	42.22
Balance at December 31, 2019	33,855,948	36.19			$	640	million
Annual grant to eligible employees	2,280,440	59.04
Additional options issued	136,360	49.48
Total options granted	2,416,800	58.50
Options exercised (1)	(7,847,964)	30.55			$	205	million
Options cancelled	(672,890)	44.94
Balance at December 31, 2020	27,751,894	39.51		5 years	$	527	million
Exercisable at December 31, 2020	21,444,333	36.18		4 years	$	478	million

(1)Cash received from options exercised was $236 million in 2020, $369 million in 2019 and $231 million in 2018. The actual tax benefit realized and recorded in the provision for income taxes for the tax deductions from the option exercises totaled $27 million in 2020, $40 million in 2019 and $21 million in 2018.

Deferred Stock Units, Performance Share Units and Restricted Stock:

Historically we have made grants of deferred stock units, performance share units and restricted stock. Beginning in 2016, we only grant deferred stock units and performance share units and no longer grant restricted stock. Deferred stock units granted to eligible employees have most shareholder rights, except that they may not sell, assign, pledge or otherwise encumber the shares and our deferred stock units do not have voting rights until vested. Shares of deferred stock units are subject to forfeiture if certain employment conditions are not met. Deferred stock units generally vest on the third anniversary of the grant date. Performance share units granted under our 2005 Plan vest based on varying performance, market and service conditions. The unvested performance share units have no voting rights and do not pay dividends. Dividend equivalents accumulated over the vesting period are paid only after the performance share units vest.

The fair value of the deferred stock units, performance share units and restricted stock at the date of grant is amortized to earnings over the vesting period. The fair value of our deferred stock units and restricted stock is measured at the market price of our Common Stock on the grant date. Performance share unit awards generally have targets tied to both performance and market-based conditions. For market condition components, market volatility and other factors are taken into consideration in determining the grant date fair value and the related compensation expense is recognized regardless of whether the market condition is satisfied, provided that the requisite service has been provided. For performance condition components, we estimate the probability that the performance conditions will be achieved each quarter and adjust compensation expenses accordingly. The grant date fair value of performance share units is determined based on the Monte Carlo simulation model for the market-based total shareholder return component and the market price of our Common Stock on the grant date for performance-based components. The number of performance share units that ultimately vest ranges from 0-200 percent of the number granted, based on the achievement of the performance and market-based components.

We recorded compensation expense related to deferred stock units, performance share units and restricted stock of $98 million in 2020, $97 million in 2019 and $85 million in 2018 in our results from continuing operations. The deferred tax benefit recorded related to this compensation expense was $15 million in 2020, $16 million in 2019 and $12 million in 2018. The unamortized compensation expense related to our deferred stock units, performance share units and restricted stock was $107 million at December 31, 2020 and is expected to be recognized over a weighted-average period of 1.7 years.

Our performance share unit, deferred stock unit and restricted stock activity is reflected below:


	Number of Shares	Grant Date	Weighted-Average Fair Value Per Share (4)		Weighted-Average Aggregate Fair Value (3)
Balance at January 1, 2018	7,669,705		$	39.74
Annual grant to eligible employees:		Feb. 22, 2018
Performance share units	1,048,770		51.23
Deferred stock units	788,310		43.51
Additional shares granted (1)	446,752	Various	41.78
Total shares granted	2,283,832		46.72		$	107	million
Vested (2) (3)	(2,511,992)		38.91		$	98	million
Forfeited (2)	(882,535)		42.00
Balance at December 31, 2018	6,559,010		42.19
Annual grant to eligible employees:		Feb. 22, 2019
Performance share units	891,210		57.91
Deferred stock units	666,880		47.72
Additional shares granted (1)	205,073	Various	54.81
Total shares granted	1,763,163		53.69		$	95	million
Vested (2) (3)	(2,007,848)		37.81		$	76	million
Forfeited (2)	(652,380)		45.88
Balance at December 31, 2019	5,661,945		46.90
Annual grant to eligible employees:		Feb. 20, 2020
Performance share units	825,230		65.83
Deferred stock units	545,550		59.04
Additional shares granted (1)	390,730	Various	56.90
Total shares granted	1,761,510		61.75		$	109	million
Vested (3)	(2,051,054)		42.87		$	88	million
Forfeited	(475,411)		48.24
Balance at December 31, 2020	4,896,990		53.80

(1)Includes performance share units and deferred stock units.

(2)Includes performance share units, deferred stock units and historically granted restricted stock.

(3)The actual tax benefit/(expense) realized and recorded in the provision for income taxes for the tax deductions from the shares vested totaled $5 million in 2020, $2 million in 2019 and $3 million in 2018.

(4)The grant date fair value of performance share units is determined based on the Monte Carlo simulation model for the market-based total shareholder return component and the closing market price of the Company’s stock on the grant date for performance-based components. The Monte Carlo simulation model incorporates the probability of achieving the total shareholder return market condition. Compensation expense is recognized using the grant date fair values regardless of whether the market condition is achieved, so long as the requisite service has been provided.